A nonanthracycline-containing chemotherapy regimen combined with the targeted therapy trastuzumab (Herceptin) may be an option for some women with HER2-positive breast cancer, according to results from the Breast Cancer International Research Group 006 (BCIRG-006) trial. These results, the first from a large randomized breast cancer trial to test nonanthracycline chemotherapy with trastuzumab, were reported October 6 in the New England Journal of Medicine. Read more > >
- Public Comment Sought on Draft Prostate Cancer Screening Recommendation
- Public Comment Sought on Updated Cervical Cancer Screening Recommendations
- NCI Recognizes Community Physician J. Philip Kuebler
- Meet NCI Experts at the American Public Health Association Annual Meeting
- Summit on Cell Therapy for Cancer Slated for November
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at email@example.com.